Disease progression in C9orf72 mutation carriers

Neurology. 2017 Jul 18;89(3):234-241. doi: 10.1212/WNL.0000000000004115. Epub 2017 Jun 14.

Abstract

Objective: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes.

Methods: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months.

Results: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up.

Conclusions: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.

MeSH terms

  • Adult
  • Amyotrophic Lateral Sclerosis / diagnosis
  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / physiopathology*
  • Amyotrophic Lateral Sclerosis / psychology*
  • C9orf72 Protein
  • DNA Repeat Expansion
  • Diagnosis, Differential
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Frontotemporal Dementia / diagnosis
  • Frontotemporal Dementia / genetics
  • Frontotemporal Dementia / physiopathology*
  • Frontotemporal Dementia / psychology*
  • Heterozygote*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Motor Activity
  • Neuropsychological Tests
  • Phenotype
  • Prospective Studies
  • Proteins / genetics*
  • Severity of Illness Index
  • Survival Analysis

Substances

  • C9orf72 Protein
  • C9orf72 protein, human
  • Proteins